Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.88 |
| ▸ | THRB | P10828 | 1/20 | 0.88 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.58 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexane SCHEMBL9557662 | 1.00 | TSHR (0.88) | TSHRTHRBLMNASLC22A1SLC22A2 | |
| Hexane SCHEMBL8705498 | 1.00 | TSHR (0.88) | TSHRTHRBLMNASLC22A1SLC22A2 | |
| Hexane SCHEMBL5017645 | 1.00 | TSHR (0.88) | TSHRTHRBLMNASLC22A1SLC22A2 | |
| Hexane SCHEMBL11650566 | 1.00 | TSHR (0.88) | TSHRTHRBLMNASLC22A1SLC22A2 | |
| Hexane SCHEMBL399 | 1.00 | — | — | |
| Hexane SCHEMBL8151140 | 1.00 | TSHR (0.88) | TSHRTHRBLMNASLC22A1SLC22A2 | |
| Hexane SCHEMBL9859565 | 1.00 | TSHR (0.88) | TSHRTHRBLMNASLC22A1SLC22A2 | |
| Tetradecane SCHEMBL25387874 | 0.94 | TSHR (1.00) | TSHRTHRBLMNASLC22A1DNM1 | |
| Decane SCHEMBL23499900 | 0.94 | TSHR (1.00) | TSHRTHRBLMNASLC22A1DNM1 | |
| Hexane SCHEMBL23175213 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 506 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116730959-A | Novel photosensitive precursor dianhydride structure and synthesis method thereof | 苏州明扬半导体材料有限公司 | 2023-09-12 | — | — | CN | claimed |
| WO-2023003291-A1 | METHOD FOR PREPARING NATURAL BIODEGRADABLE SUPERABSORBENT POLYMER AND USE THEREOF | (주)마린패드 | 2023-01-26 | — | — | WO | claimed |
| CN-111807941-B | Method for synthesizing alpha-diketone compound by catalyzing with metal salt | 武汉理工大学 | 2022-07-05 | — | — | CN | claimed |
| CN-111937870-A | Attractant suitable for trapping aphids in carpinus europaeus and application of attractant | 江苏开放大学（江苏城市职业学院） | 2020-11-17 | — | — | CN | claimed |
| CN-108793100-A | Atomic-level thickness graphene/boron nitride composite heterogeneous film transfer method | 中国人民解放军国防科技大学 | 2018-11-13 | — | — | CN | claimed |
| CN-104630297-B | A kind of enzyme process nonaqueous phase catalyzes and synthesizes (R) -3-TBDMSO glutaric acid first monoesters and its derivative | 江南大学 | 2018-07-06 | — | — | CN | claimed |
| CN-108048211-A | A kind of grease extraction of high oil recovery | 山东江天生物科技有限公司 | 2018-05-18 | — | — | CN | claimed |
| CN-107001520-A | Processing method for recycling polystyrene waste | 波利斯太沃特公司 | 2017-08-01 | — | — | CN | claimed |
| CN-101272684-A | Methods and compositions for the treatment of neuropathies and related disorders | DOV PHARMACEUTICAL INC (US) | 2008-09-24 | — | — | CN | claimed |
| US-4855529-A | USING MOLECULAR SIEVE TO SEPARATE. | SHELL OIL COMPANY (US) | 1989-08-08 | — | — | US | claimed |
| CN-122055371-A | Faster automated iterative C-C bond formation | 伊利诺伊大学评议会 | 2026-05-15 | — | — | CN | disclosed |
| US-12600844-B2 | Linear low density polyethylene for film applications | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260028651-A1 | METHOD OF PRODUCING & PROCESSING DIAMINES | AGAIN BIO APS (DK) | 2026-01-29 | — | — | US | disclosed |
| US-12503711-B2 | Method of producing and processing diamines to a diamine free base using a carbonate intermediate and an engineered microorganism | GENOMATICA, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250353865-A1 | AMINE ADDUCTS OF GROUP 2 METALLOCENE PRECURSORS FOR DEPOSITON OF GROUP 2 METAL FILMS | Ereztech LLC (US) | 2025-11-20 | — | — | US | disclosed |
| US-4195069-A | Preparation of violet TiCl3 | SHELL OIL COMPANY (US) | 1980-03-25 | — | — | US | disclosed |
| US-4180584-A | ANALGESIC; NARCOTIC ANTAGONIST | THE UPJOHN COMPANY (US) | 1979-12-25 | — | — | US | disclosed |
| US-4111836-A | PROCESS FOR FORMING HIGH PERFORMANCE TITANIUM TRICHLORIDE OLEFIN POLYMERIZATION CATALYST COMPONENTS | STANDARD OIL COMPANY (INDIANA) (US) | 1978-09-05 | — | — | US | disclosed |
| US-4107418-A | OF AN ACRYLIC MONOMER AND ANOTHER UNSATURATED MONOMER; CATALYST COMPRISING AN ORGANOALUMINUM HALIDE AND ORGANIC PEROXIDE | MITSUI PETROCHEMICAL INDUSTRIES LTD. (JP) | 1978-08-15 | — | — | US | disclosed |
| US-4065573-A | ANALGESICS | THE UPJOHN COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353865-A1 | AMINE ADDUCTS OF GROUP 2 METALLOCENE PRECURSORS FOR DEPOSITON OF GROUP 2 METAL FILMS | AOC2, CDCA2, ALKBH2 | TSHR 4841/4885THRB 4821/4885LMNA 1531/4885 |
| US-20260028651-A1 | METHOD OF PRODUCING & PROCESSING DIAMINES | DDC, DAO, ODC1 | TSHR 3382/4885THRB 311/4885LMNA 2536/4885 |
| US-12600844-B2 | Linear low density polyethylene for film applications | RPS2, RPSA, LBR | TSHR 270/4885THRB 1480/4885LMNA 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.